Article
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
European journal of gastroenterology & hepatology - 1 Aug 2020
Elsadek Hany M, Abdelbaser Elsayed S, Emara Mohamed H, Soliman Hanan H, Farag Alaa A
Abstract excerpt
BACKGROUND: Though direct-acting antiviral agents (DAAs) therapy is associated with a high cure rate of hepatitis C virus infection, a potential risk of serious adverse events (SAEs) exists. The aim of this study was to determine the incidence and predictors of morbidity and mortality related to DAAs therapy. METHODS: This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.